Diagnostic and Management Strategies for Invasive Aspergillosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00816088 |
Recruitment Status
:
Completed
First Posted
: December 31, 2008
Last Update Posted
: December 23, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Invasive Aspergillosis Neutropenia |

Study Type : | Observational |
Actual Enrollment : | 203 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Diagnostic and Management Strategies for Invasive Aspergillosis in Neutropenic Adult Haemato-Oncology Patients With a Proposal for Investigation of a Novel Potential Marker for Early Diagnosis: a Prospective Cohort Study |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | December 2011 |
Actual Study Completion Date : | December 2011 |

Group/Cohort |
---|
neutropenia
Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
|
- To determine the incidence of IFD using a comprehensive diagnostic approach [ Time Frame: 3 years ]
- Evaluation of established and experimental diagnostic methods [ Time Frame: 2-3 years ]
- Costing analysis [ Time Frame: 2-3 years ]
- Establish the prognostic value of CT appearances in patients with IA [ Time Frame: 2-3 years ]
- Assessing the value of methylene blue 'tattooing' prior to surgical biopsy [ Time Frame: 2-3 years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All adult haemato-oncology patients admitted for transplant or high dose chemotherapy and able to consent.
Exclusion Criteria:
- children (< 18 years old) or inability or refusal to consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00816088
United Kingdom | |
King's College Hospital NHS Foundation Trust | |
London, United Kingdom, SE5 9RS |
Principal Investigator: | M.Mansour Ceesay, FRCPath | Kings College Hospital | |
Principal Investigator: | Antonio Pagliuca, FRCPath | Kings College Hospital | |
Principal Investigator: | Jim Wade, FRCPath | Kings College Hospital | |
Principal Investigator: | Melvyn Smith, PhD | Kings College Hospital | |
Principal Investigator: | Sujal Desai, FRCR | Kings College Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mansour Ceesay, Clinical Research Fellow, King's College Hospital NHS Trust |
ClinicalTrials.gov Identifier: | NCT00816088 History of Changes |
Other Study ID Numbers: |
08/H0808/154 08HA11 |
First Posted: | December 31, 2008 Key Record Dates |
Last Update Posted: | December 23, 2014 |
Last Verified: | December 2014 |
Keywords provided by Mansour Ceesay, King's College Hospital NHS Trust:
chemotherapy Stem cell transplantation |
Additional relevant MeSH terms:
Neutropenia Aspergillosis Agranulocytosis Leukopenia Leukocyte Disorders Hematologic Diseases |
Mycoses Hyalohyphomycosis Dermatomycoses Lung Diseases, Fungal Skin Diseases, Infectious Skin Diseases |